Submit the valoctocogene roxaparvovec Marketing Authorization Application to the EMA
No public evidence found either way
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 25 Feb 2021
- Due
- 30 Jun 2021
- Last checked
- 26 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“BioMarin is targeting submission of the Marketing Authorization Application (MAA) with these results to the EMA in the second quarter of 2021 pending confirmation in presubmission meetings.”
What we found
After 4 checks we found no clear public record either way, so this commitment is not counted as met or not met.
If you have a public source showing the outcome, please send it to us.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory submission
- Indicative materiality
- High rules
- Action
- Submit
- Deliverable
- Marketing Authorization Application for valoctocogene roxaparvovec to EMA
- Where
- Europe
- Language
- Aspirational (“aims”, “intends”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: pending confirmation in presubmission meetings
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Biomarin Pharmaceutical Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-BMRN-024412 · Corrections policy